NADAC acquisition cost data for FEMYNOR 28 TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 69238155106 | $0.1406 | 2022-12-21 | Rx |
| 69238155106 | $0.1406 | 2022-12-21 | Rx |
Generic: Norgestimate-Ethinyl Estradiol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $90.2K | 3,531 | 962 | $0.5020 |
| 2020 | $112.0K | 3,430 | 930 | $0.5943 |
| 2021 | $25.1K | 1,050 | 360 | $0.5292 |
| 2022 | $15.3K | 725 | 194 | $0.5349 |
| 2023 | $3.3K | 147 | 76 | $0.5929 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $504.92 | 22 | N/A |
| Florida | $402.44 | 13 | N/A |
| Ohio | $323.81 | 14 | N/A |
| Indiana | $243.91 | 15 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.